Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

HIV B Cell Function

Financiado

Cerrado

Understanding HIV specific B cell function and viral immunogenicity

I will establish how abnormal B cell behaviour contributes to the generation of HIV neutralising antibodies by studying B cell biology: Previous studies show that broadly neutralising HIV antibodies are the most highly-mutated hum... ver más

31/05/2024

UNIVERSITY COLLEGE...

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

UNIVERSITY COLLEGE LONDON No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-05-31

ERC-2017-STG: ERC Starting Grant

I+D

Cerrada hace 8 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

UNIVERSITY COLLEGE LONDON

1.50M€ | Lider

INDUSTRIA JABONERA LINA

550.11K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

B-INNATE Innate signaling networks in B cell antibody production new... 2M€ Cerrado

PostTransGC Post transcriptional and post translational mechanisms under... 2M€ Cerrado

PID2021-128244OB-I00 REDES DE MICRORNAS REGULADORAS EN TOLERANCIA DE CELULAS B Y... 345K€ Cerrado

HIV1ABTHERAPY Antibody Mediated Therapy of HIV 1 Infection 2M€ Cerrado

3W-RGB Identification of whether in which aspects and by which fu... 300K€ Cerrado

RYC2021-031642-I Role of B cells in Inflammation, Infection and Cancer Immune... 236K€ Cerrado

Duración del proyecto: 75 meses Fecha Inicio: 2018-02-19
Fecha Fin: 2024-05-31

Líder del proyecto

UNIVERSITY COLLEGE LONDON No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 1M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto I will establish how abnormal B cell behaviour contributes to the generation of HIV neutralising antibodies by studying B cell biology: Previous studies show that broadly neutralising HIV antibodies are the most highly-mutated human antibodies ever isolated, with unusually long binding loops and polyreactivity, suggestive of changes to B cell tolerance and germinal centre selection mechanisms. These remarkable antibodies develop only during HIV infection, concurrent with immune dysfunction, not following vaccination. Crucially, the cellular processes whereby these antibodies arise need to be elucidated and I hypothesize that doing so using RNAseq, flow cytometry and imaging B cell activation will answer why only a minority of HIV+ individuals develop neutralization breadth. Moreover, B cell dysfunction is associated to a range of malignancies and autoimmune diseases and, while much has been learnt from model antigens in mouse models, HIV infection provides a uniquely well-characterised human model to study B cell regulation. Another fundamental question is whether strain-specific antibodies are a stepping-stone to breadth, or a detour that must be eliminated in vaccination. I have shown that the best serum neutralization activity induced via stabilized HIV envelope protein immunization predominantly targets a strain-specific glycan hole, similar to many early responses observed in infection before broad neutralising activity develops. Therefore, I will determine whether non-neutralising and strain-specific antibodies affect the development of breadth by isolating a range of antibodies raised during viral infection from individual donors and comparing binding affinities, clonal ontogenies and B cell receptor activation. Defining the impact of competition between antibody specificities during HIV infection will be directly translatable to developing vaccines for other pathogens where cross-reactivity is a key factor such as Influenza, Dengue and Zika viruses.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores